Overview of the Situation#
Novo Nordisk A/S experienced a 2.8% decline in its stock price on Tuesday after receiving a warning letter from the U.S. Food and Drug Administration (FDA). The letter highlighted serious violations related to the company's reporting of adverse drug experiences following the marketing of its products.
Details of the FDA Warning#
The FDA's warning letter, issued on March 5, 2026, stemmed from an inspection conducted between January 13 and February 7, 2025. During this inspection, the FDA found that Novo Nordisk did not adequately report serious adverse events associated with its products, including semaglutide and liraglutide. These adverse events include serious health issues such as stroke and suicidal thoughts.
Reporting Violations#
The FDA criticized Novo Nordisk for failing to develop proper procedures for monitoring and reporting adverse drug experiences. Specifically, the company did not report serious incidents to the FDA within the required 15-day period. The FDA also noted that the company's procedures allowed for the rejection of reports if they were deemed unrelated to the product, which is against FDA regulations.
Company's Response#
In response to the FDA's concerns, Novo Nordisk has submitted several corrective action plans between March 2025 and January 2026. These plans included revising reporting procedures and conducting reviews of past cases. However, the FDA found these responses insufficient, stating that they lacked the necessary details to ensure future compliance. The FDA has requested a follow-up response from Novo Nordisk within 15 business days to outline further actions to prevent similar issues.